2020 Q3 Form 10-Q Financial Statement

#000156459020042908 Filed on September 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3
Revenue $50.11M $56.41M
YoY Change -11.16% -9.71%
Cost Of Revenue $19.20M $23.97M
YoY Change -19.91% -2.0%
Gross Profit $31.00M $32.44M
YoY Change -4.43% -14.67%
Gross Profit Margin 61.86% 57.5%
Selling, General & Admin $13.40M $12.43M
YoY Change 7.85% -1.12%
% of Gross Profit 43.23% 38.31%
Research & Development $33.50M $30.42M
YoY Change 10.12% -5.32%
% of Gross Profit 108.06% 93.78%
Depreciation & Amortization $600.0K $700.0K
YoY Change -14.29% 16.67%
% of Gross Profit 1.94% 2.16%
Operating Expenses $46.90M $42.85M
YoY Change 9.46% -4.14%
Operating Profit -$15.90M -$10.41M
YoY Change 52.77% 55.76%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.300M $2.195M
YoY Change -40.77% 199.86%
Pretax Income -$14.01M -$8.213M
YoY Change 70.57% 38.03%
Income Tax $700.0K $1.978M
% Of Pretax Income
Net Earnings -$14.76M -$10.19M
YoY Change 44.79% 48.19%
Net Earnings / Revenue -29.45% -18.07%
Basic Earnings Per Share -$0.43 -$0.31
Diluted Earnings Per Share -$0.43 -$0.31
COMMON SHARES
Basic Shares Outstanding 34.48M 32.86M
Diluted Shares Outstanding 34.48M 32.86M

Balance Sheet

Concept 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $410.7M $375.8M
YoY Change 9.29% -0.04%
Cash & Equivalents $220.6M $222.7M
Short-Term Investments $190.1M $153.1M
Other Short-Term Assets $3.500M $4.500M
YoY Change -22.22% 66.67%
Inventory $23.91M $17.38M
Prepaid Expenses
Receivables $23.30M $27.94M
Other Receivables $0.00 $0.00
Total Short-Term Assets $461.4M $425.6M
YoY Change 8.41% -2.92%
LONG-TERM ASSETS
Property, Plant & Equipment $5.027M $6.105M
YoY Change -17.66% -12.79%
Goodwill $26.60M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.60M $5.246M
YoY Change 197.37% -16.73%
Total Long-Term Assets $72.00M $64.61M
YoY Change 11.43% 23.54%
TOTAL ASSETS
Total Short-Term Assets $461.4M $425.6M
Total Long-Term Assets $72.00M $64.61M
Total Assets $533.4M $490.2M
YoY Change 8.81% -0.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.70M $18.91M
YoY Change -27.56% -19.18%
Accrued Expenses $35.60M $26.70M
YoY Change 33.33% 15.58%
Deferred Revenue $553.0K
YoY Change -5.15%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.20M $47.24M
YoY Change 8.38% -0.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.68M $9.431M
YoY Change 76.84% 4.79%
Total Long-Term Liabilities $16.68M $9.431M
YoY Change 76.84% 4.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.20M $47.24M
Total Long-Term Liabilities $16.68M $9.431M
Total Liabilities $74.80M $61.77M
YoY Change 21.09% 6.87%
SHAREHOLDERS EQUITY
Retained Earnings $203.4M
YoY Change
Common Stock $224.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $458.6M $428.5M
YoY Change
Total Liabilities & Shareholders Equity $533.4M $490.2M
YoY Change 8.81% -0.1%

Cashflow Statement

Concept 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$14.76M -$10.19M
YoY Change 44.79% 48.19%
Depreciation, Depletion And Amortization $600.0K $700.0K
YoY Change -14.29% 16.67%
Cash From Operating Activities -$2.400M $8.100M
YoY Change -129.63% 17.39%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K -$500.0K
YoY Change -40.0% -61.54%
Acquisitions
YoY Change
Other Investing Activities -$14.20M $9.200M
YoY Change -254.35% -387.5%
Cash From Investing Activities -$14.40M $8.800M
YoY Change -263.64% -300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 900.0K 1.500M
YoY Change -40.0% -103.42%
NET CHANGE
Cash From Operating Activities -2.400M 8.100M
Cash From Investing Activities -14.40M 8.800M
Cash From Financing Activities 900.0K 1.500M
Net Change In Cash -15.90M 18.40M
YoY Change -186.41% -144.55%
FREE CASH FLOW
Cash From Operating Activities -$2.400M $8.100M
Capital Expenditures -$300.0K -$500.0K
Free Cash Flow -$2.100M $8.600M
YoY Change -124.42% 4.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
344000
CY2020Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1000000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15214000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-363000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16294000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15463000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1182000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
455583000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y5M23D
amba Proceeds From Issuance Of Shares Under Incentive Equity Plan And Employee Stock Purchase Plan
ProceedsFromIssuanceOfSharesUnderIncentiveEquityPlanAndEmployeeStockPurchasePlan
3866000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15032000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
194000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
254000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-17311000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
422438000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
988000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-10191000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
428461000
us-gaap Profit Loss
ProfitLoss
-30219000
us-gaap Profit Loss
ProfitLoss
-27502000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5786000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5439000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-88000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
696000
us-gaap Share Based Compensation
ShareBasedCompensation
32430000
us-gaap Share Based Compensation
ShareBasedCompensation
32660000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
188000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
170000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
72000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-87000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4788000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1728000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
936000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-876000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1472000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1541000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194058000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1217000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6111000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-180000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
90000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
699000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
923000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5222000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13419000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
109161000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
91143000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
44044000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
32573000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
49227000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
71395000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16555000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11871000
amba Proceeds From Issuance Of Shares Under Incentive Equity Plan And Employee Stock Purchase Plan
ProceedsFromIssuanceOfSharesUnderIncentiveEquityPlanAndEmployeeStockPurchasePlan
5429000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1283000
amba Capital Expenditures Incurred But Not Yet Paid And Financing Incurred For Tangible And Intangible Asset Purchased
CapitalExpendituresIncurredButNotYetPaidAndFinancingIncurredForTangibleAndIntangibleAssetPurchased
347000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-329000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2834000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2144000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-288000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
24000
amba Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1031000
amba Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1454000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
529000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
954000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10755000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
231412000
us-gaap Income Taxes Paid
IncomeTaxesPaid
842000
amba Capital Expenditures Incurred But Not Yet Paid And Financing Incurred For Tangible And Intangible Asset Purchased
CapitalExpendituresIncurredButNotYetPaidAndFinancingIncurredForTangibleAndIntangibleAssetPurchased
1174000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
222693000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194047000
CY2019Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q1 amba Available For Sale Securities Debt Maturities Within One Year
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear
146267000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5614000
us-gaap Depreciation
Depreciation
1300000
us-gaap Depreciation
Depreciation
1400000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14373000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211081000
CY2020Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
10133000
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12838000
CY2020Q1 us-gaap Inventory Net
InventoryNet
22971000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13228000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16874000
CY2020Q3 amba Accrued Rebates
AccruedRebates
133000
CY2020Q1 amba Accrued Rebates
AccruedRebates
54000
CY2020Q3 amba Accrued Development Cost Liabilities
AccruedDevelopmentCostLiabilities
12232000
CY2020Q1 amba Accrued Development Cost Liabilities
AccruedDevelopmentCostLiabilities
10885000
CY2020Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Current
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueCurrent
5041000
CY2020Q1 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Current
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueCurrent
4388000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2522000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2769000
CY2020Q3 amba Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
33156000
CY2020Q1 amba Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
34970000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15472000
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19987000
CY2019Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
9000
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
11000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222702000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reported periods. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, management evaluates its estimates and assumptions, including those related to (i) the collectability of accounts receivable; (ii) write down of excess and obsolete inventories; (iii) intangible assets and goodwill; (iv) the estimated useful lives of long-lived assets; (v) impairment of long-lived assets and financial instruments; (vi) warranty obligations; (vii) the valuation of stock-based compensation awards and financial instruments; (viii) the probability of performance objectives achievement; (ix) the realization of tax assets and estimates of tax liabilities, including reserves for uncertain tax positions; and (x) the recognition and disclosure of contingent liabilities. These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material.</p> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also assessed the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impacts </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the above accounting matters </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as of July</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020 and through the date of this report. While </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is difficult to quantify the impact of COVID-19</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">magnitude and duration of COVID-19, as well as other </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors, could r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">esult in material negative impacts to its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed consolidated financial statements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in future reporting periods.</span></p>
CY2020Q3 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
212429000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1631000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
44000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214016000
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
210313000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
770000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211081000
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214016000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211081000
CY2020Q3 amba Available For Sale Securities Debt Maturities Within One Year
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear
139040000
CY2020Q3 amba Available For Sale Securities Debt Maturities Within One To Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneToThreeYearsFairValue
74976000
CY2020Q1 amba Available For Sale Securities Debt Maturities Within One To Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneToThreeYearsFairValue
64814000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214016000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214016000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211081000
CY2020Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
15085000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8822000
CY2020Q3 us-gaap Inventory Net
InventoryNet
23907000
CY2020Q3 us-gaap Depreciation
Depreciation
600000
CY2019Q3 us-gaap Depreciation
Depreciation
700000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20499000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5027000
CY2020Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Current
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueCurrent
5000000.0
CY2020Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
6500000
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
22476000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6388000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16088000
CY2020Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31303000
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13477000
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17826000
CY2020Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2019Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2020Q3 amba Lease Liabilities Arising From Obtaining Right Of Use Assets For Operating Lease
LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsForOperatingLease
88000
amba Lease Liabilities Arising From Obtaining Right Of Use Assets For Operating Lease
LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsForOperatingLease
176000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
342000
us-gaap Operating Lease Payments
OperatingLeasePayments
1031000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M3D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0443
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1390000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2419000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1681000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1699000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1746000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1227000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10162000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
849000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9313000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
175800000
CY2020Q3 amba Unrecognized Tax Benefits Including Interest
UnrecognizedTaxBenefitsIncludingInterest
8445000
CY2020Q1 amba Unrecognized Tax Benefits Including Interest
UnrecognizedTaxBenefitsIncludingInterest
8261000
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1287000
CY2020Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1288000
CY2020Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
6533000
CY2020Q1 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
8159000
CY2020Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
413000
CY2020Q1 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
68000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16678000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17776000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00045
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00045
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2016Q2 amba Stock Repurchase Program Inception Month And Year
StockRepurchaseProgramInceptionMonthAndYear
2016-06
CY2020Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
275000000.0
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32430000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32660000
CY2020Q3 amba Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
100000
amba Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
900000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
82.55
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1027367
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16394000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
23600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
53.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.73
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99911
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4293000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7115
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
48.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
13853
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.41
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15936000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
885276
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
31.99
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15670000
CY2020Q3 amba Closing Market Price Of Ordinary Shares On Nasdaq On Last Day Of Reporting Period
ClosingMarketPriceOfOrdinarySharesOnNASDAQOnLastDayOfReportingPeriod
45.28
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14756000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-10191000
us-gaap Net Income Loss
NetIncomeLoss
-30219000
us-gaap Net Income Loss
NetIncomeLoss
-27502000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34480307
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32860974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34280318
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32676509
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34480307
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32860974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34280318
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32676509
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24258000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2030787
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1954980
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2137555
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1950833
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14009000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8213000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28346000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
747000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1978000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1873000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3244000
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.053
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.241
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.066
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.134
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
43100000
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
24400000
CY2020Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
35900000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50113000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56410000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104758000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103598000

Files In Submission

Name View Source Status
0001564590-20-042908-index-headers.html Edgar Link pending
0001564590-20-042908-index.html Edgar Link pending
0001564590-20-042908.txt Edgar Link pending
0001564590-20-042908-xbrl.zip Edgar Link pending
amba-10q_20200731.htm Edgar Link pending
amba-10q_20200731_htm.xml Edgar Link completed
amba-20200731.xsd Edgar Link pending
amba-20200731_cal.xml Edgar Link unprocessable
amba-20200731_def.xml Edgar Link unprocessable
amba-20200731_lab.xml Edgar Link unprocessable
amba-20200731_pre.xml Edgar Link unprocessable
amba-ex311_8.htm Edgar Link pending
amba-ex312_6.htm Edgar Link pending
amba-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending